Regeneron & CytomX Expand Bispecific Cancer Collaboration, Targeting $4B Milestone
Regeneron expands its CytomX partnership, adding new targets and funding to create safer, tumor‑specific bispecific therapies—pushing precision oncology forward with a $4 billion potential milestone value.
4 minutes to read